Investor Polar Capital Holdings Plc
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Polar Capital Holdings Plc . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-09-04 13G/A HGTY / Hagerty, Inc. 0 5,306,865
2025-08-14 13G/A HGTY / Hagerty, Inc. 5,002,477 0
2025-08-14 13G/A ARQT / Arcutis Biotherapeutics, Inc. 6,706,475 5,006,472
2025-08-14 13G ELVN / Enliven Therapeutics, Inc. 2,389,668 2,536,881
2025-05-15 13G NPCE / NeuroPace, Inc. 2,972,003
2025-05-15 13G/A ARQT / Arcutis Biotherapeutics, Inc. 6,297,688 6,706,475
2025-02-14 13G/A VTEX / VTEX 10,538,673 5,232,020
2025-02-14 13G/A ELVN / Enliven Therapeutics, Inc. 2,687,797 2,389,668
2024-11-13 13G/A CLDX / Celldex Therapeutics, Inc. 3,135,871 2,711,163
2024-11-13 13G/A BRKR / Bruker Corporation 317,928
2024-11-13 13G/A AVDL / Avadel Pharmaceuticals plc 6,751,782 4,803,899
2024-11-13 13G VTEX / VTEX 10,538,673
2024-11-13 13G HGTY / Hagerty, Inc. 5,002,477
2024-11-13 13G ELVN / Enliven Therapeutics, Inc. 2,687,797
2024-02-13 13G CLDX / Celldex Therapeutics, Inc. 3,135,871
2024-02-13 13G/A SYRE / Spyre Therapeutics, Inc. 500,000
2024-02-13 13G AVDL / Avadel Pharmaceuticals plc 2,794,673 6,751,782
2024-02-13 13G/A RVNC / Revance Therapeutics, Inc. 4,848,633 3,169,239
2024-02-13 13G/A ARQT / Arcutis Biotherapeutics, Inc. 7,117,944 6,297,688
2024-02-13 13G/A NSTGQ / NS Wind Down Co., Inc. 3,778,731 3,975,000
2023-11-16 13G ARQT / Arcutis Biotherapeutics, Inc. 7,117,944
2023-07-28 13G AGLE / Aeglea BioTherapeutics Inc 3,936,198
2023-07-13 13G/A NSTGQ / NS Wind Down Co., Inc. 3,778,731 3,778,731
2023-02-14 13G RVNC / Revance Therapeutics, Inc. 4,848,633
2023-02-14 13G/A SMMT / Summit Therapeutics Inc. 6,295,713 0
2023-02-14 13G/A INFIQ / Infinity Pharmaceuticals, Inc. 5,000,000 2,071,242
2023-02-14 13G NSTGQ / NS Wind Down Co., Inc. 3,778,731
2023-02-14 13G/A QTNT / Quotient Ltd 9,251,653 0
2022-02-14 13G/A BLU / Bellus Health Inc 3,500,000 2,500,000
2022-02-14 13G/A SUMM / SUMMIT THERAPEUTICS PLC 5,800,000 6,295,713
2022-02-14 13G/A / Oxford Immunotec Global PLC 2,568,385 0
2022-02-14 13G/A QTNT / Quotient Ltd 9,251,653 9,251,653
2022-02-14 13G INFI / Infinity Pharmaceuticals Inc. 5,000,000
2022-02-14 13G/A AVDL / Avadel Pharmaceuticals plc 6,027,705 2,794,673
2021-02-16 13G/A BLU / Bellus Health Inc 3,500,000
2021-02-16 13G/A / Oxford Immunotec Global PLC 2,568,385
2021-02-16 13G/A QTNT / Quotient Ltd 9,251,653
2021-02-16 13G SUMM / SUMMIT THERAPEUTICS PLC 5,800,000
2021-02-16 13G AVDL / Avadel Pharmaceuticals plc 6,027,705